Results 171 to 180 of about 437,497 (273)

Seeing radiation: Applications of an imaging survey meter in radiation oncology

Journal of Applied Clinical Medical Physics, Volume 27, Issue 10, October 2026.
Abstract Background and purpose Radiation shielding surveys require location and evaluation of radiation hotspots in shielding barriers. This process is normally done by using a conventional survey meter and slowly moving the survey meter manually across the face of the barrier.
Patrick N. McDermott, Robert C. Halford, Brayden Halvorson, Ian Lake, Jian Liang, Akin Ogretici, Avery Peterson, Evelyn Sebastian, Xiangkun Xu   +8 more
wiley   +1 more source

Direct Regioselective para‐Fluorination via I(I)/I(III) Catalysis

Angewandte Chemie, Volume 138, Issue 37, 7 September 2026.
A direct, para‐selective fluorination by I(I)/I(III) catalysis is disclosed that does not require substrate pre‐functionalization. This strategy leverages the Leonard link inherent to phenylpropanoate and phenylpropanamides to promote a spirocyclization/para‐selective sequence. The C3‐side chain maps onto a range of common drug scaffolds and allows the
Christoph Roblick, Julian D. Bendix, Timothy A. Hilton, Kathrin Bussmann, Constantin G. Daniliuc, Ryan Gilmour   +5 more
wiley   +2 more sources

Clinical applications and future directions of Iodine-131-Metaiodobenzylguanidine therapy in neuroblastoma: from salvage treatment to frontline integration. [PDF]

Ann Nucl Med
Vu HMC, Kayano D, Wakabayashi H, Kuroda R, Kinuya S.   +4 more
europepmc   +1 more source

Myasthenia Gravis and Thymoma

Muscle &Nerve, Volume 74, Issue 4, Page 1156-1173, October 2026.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Borylcyclopropanes: Synthetic Strategies and Applications

Angewandte Chemie, Volume 138, Issue 37, 7 September 2026.
Borylcyclopropanes (cyclopropanes bearing a boron substituent) sit at the intersection of two privileged frameworks in synthesis. This review provides the first exhaustive survey of their chemistry, spanning metal–carbene, nucleophilic cyclization, radical, hydroboration, and C─H activation routes, and documenting applications in medicinal chemistry ...
Aiza A. Butt, Joseph M. Ready
wiley   +2 more sources

Superior efficacy of vemurafenib combined with iodine-131 for lymph node metastatic BRAF-mutant thyroid cancer: a long-term survival analysis. [PDF]

Am J Transl Res
Wang S, Zhang B, Da X, Xu J.
europepmc   +1 more source

Impact of PD‐1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib‐Based Triple Therapy

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background and Aims The optimal sequencing of programmed cell death protein 1 (PD‐1) inhibitors relative to locoregional therapy (LRT) in unresectable hepatocellular carcinoma (uHCC) remains undefined. This study evaluated the impact of PD‐1 inhibitor timing on outcomes in patients receiving hepatic arterial infusion chemotherapy (HAIC) or ...
Jian He, Jian Chen, Bohua Yu, Fuqun Wei, Weifu Liu, Peishu Huang, Songhui Wu, Xiang You, Zhisheng Chen, Ziqi Lin, Wuhua Guo, Shaowu Zhuang, Yiping Chen, Zhongwu Chen   +13 more
wiley   +1 more source

Clinical factors affecting colonic iodine-131 distribution after radioactive iodine therapy for thyroid cancer. [PDF]

Jpn J Radiol
Takata N, Kawaguchi N, Miyagawa M, Itou A, Yamada R, Takimoto A, Kido T.   +6 more
europepmc   +1 more source

The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis. [PDF]

BMC Cancer, 2022
He H, Xu Q, Yu C.
europepmc   +1 more source

Design, Synthesis, and Biological Evaluation of Pyrazolyl Thioureas (PTUs) as SIRT1 and SIRT2 Inhibitors

ChemMedChem, Volume 21, Issue 18, 28 September 2026.
Pyrazolyl thioureas were designed and synthesized as sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) inhibitors. 6a (IC50 (SIRT1) = 5.3 µM; IC50 (SIRT2) = 2.2 µM) and 7f (IC50 (SIRT1) = 12.4 µM; IC50 (SIRT2) = 13.6 µM) showed micromolar inhibition on target enzymes and HepG2‐based assays confirmed a SIRT2‐mediated effect on tubulin acetylation. Docking studies
Matteo Lusardi, Cecilia Astigiano, Deianira Bellitto, Matteo Raineri, Giorgia Guccione, Annalisa Salis, Elena Cichero, Chiara Brullo, Marco Ponassi, Santina Bruzzone, Andrea Spallarossa   +10 more
wiley   +1 more source